Korea United Pharmaceutical announced on the 10th that it has recently received a patent for a combination of omega-3 and statin from the USPTO.
With this patent registration, Korea United Pharmaceuticals will be guaranteed the exclusive and exclusive rights of drug-related technologies including omega-3 and’Atorvastatin’ in the United States until February 2037.
In January, Korea United Pharm obtained an item license for the improved new drug’Artmac Combi Gel Soft Capsule’ to which the technology was applied.
Artmac Combigel Soft Capsule is a formulation containing omega-3 fatty acid esters and atorvastatin (Omega-3-acid ethyester and Atorvastatin), and’CombiGel’ technology (CombiGel Technology) is applied. It is a product.
A tablet containing a statin drug, a treatment for hyperlipidemia, was inserted into a soft capsule. You can also visually check the form of the pill in the capsule.
The patent registered this time is a formulation technology in which tablets coated with an oilproof base are put in a soft capsule. It was developed as a combination formulation with improved drug stability compared to existing formulations. By blocking external contact with moisture, air, etc., the drug content is prevented from decreasing and stability is improved.
Currently, two patents (registration numbers: 1752700, 1950907) related to the technology of formulations containing tablets in soft capsules are registered in Korea. Overseas, patents have been registered in Japan and Vietnam as well as in the United States, which was registered at this time, and are guaranteed the exclusive rights of drug-related technologies in Japan by 2037 and Vietnam by 2035 (Japanese registration number: 6796147, Vietnam registration number: 26579). It has also been applied for and is being examined in China, Europe, Thailand, and the Philippines.